BioCentury | Sep 30, 2020
Distillery Therapeutics

An FGF21, GLP-1 fusion protein for diabetes, obesity

...By Claire Quang, Staff Writer DISEASE CATEGORY: Endocrine/metabolicINDICATION: Diabetes; obesityA fusion protein comprising FGF21 and GLP-1...
...elastin-like polypeptide could treat diabetes and obesity. In HEK cells, the fusion protein agonized the FGF21...
...improved glucose tolerance and reduced weight gain and HbA1c levels compared with FGF21 or GLP-1 monotherapy.TARGET/MARKER/PATHWAY: Fibroblast growth factor 21 (FGF21)...
BioCentury | Sep 16, 2020
Deals

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

...to 70% versus placebo. Treatment with the FGF21...
BioCentury | Sep 2, 2020
Deals

NASH therapy from Novartis adds 15th program to Boston Pharmaceuticals’ pipeline

...in 2015.The deal gives Boston Pharmaceuticals Inc. worldwide development and commercialization rights to BOS-580, a preclinical FGF21...
...Genfit S.A. (Euronext:GNFT; NASDAQ:GNFT) (see “NASH Pipeline”). “This drug in particular was engineered as a long-acting FGF21...
BioCentury | Jul 1, 2020
Product Development

Histology data builds on growing confidence around Akero’s NASH candidate

...The stock move brought the company’s market cap to $957 million. Efruxifermin (AKR-001), Akero’s long-acting FGF21...
...FGF21 - Fibroblast growth factor 21 FXR (NR1H4) - Farnesoid X receptor Lauren Martz, Senior Editor AKR-001 Akero Therapeutics Inc. Intercept Pharmaceuticals Inc. Fibroblast growth factor 21 (FGF21)...
BioCentury | Apr 4, 2020
Finance

Pandemic upends norms for public fund-raising in election year

...about $115 million in value when it announced positive Phase II data for its long-acting FGF21...
...EPS consensus estimates; 3Q19-1Q20 calculated from full-year 2020 estimates. Source: Yahoo! Finance Targets FGF21 - Fibroblast growth factor 21 Stephen...
BioCentury | Apr 1, 2020
Product Development

Akero reports positive Phase IIa data for NASH; pandemic delays expansion cohort

...to relative reductions in liver fat and alanine aminotransferase (ALT) levels. AKR-001 is a long-acting FGF21...
...for Type II diabetes (see “NASH Play Akero Emerges From Stealth” ). Targets FGF21 - Fibroblast growth factor 21...
...receptor 2 FGFR3 (CD333) - Fibroblast growth factor (FGF) receptor 3 Hongjiang Li, Staff Writer AKR-001 Akero Therapeutics Inc. Fibroblast growth factor 21 (FGF21) Fibroblast...
BioCentury | Feb 26, 2020
Distillery Therapeutics

Boosting FGF21 signaling to treat pancreatitis

...FGF21 replacement therapy or inhibition of PERK-mediated FGF21 repression could treat pancreatitis. Pancreatic levels of FGF21...
...or chronic pancreatitis than in 14 healthy individuals. In three mouse models of pancreatitis, recombinant FGF21...
...inhibitor tool compound led to similar results in one of the models. At least two FGF21...
BioCentury | Jan 10, 2020
Company News

Boehringer continues fibrosis drive via acquisition of Enleofen assets

...IL-11 - Interleukin-11; IL11RA - Interleukin-11 receptor subunit α; ENPP2 (ATX) - Autotaxin; FGF21 - Fibroblast growth factor 21...
BioCentury | Nov 11, 2019
Financial News

Aftermarket pop for 89bio following delayed IPO

...a target of interest that addresses an unmet need: BIO89-100, a long-acting glycopegylated analog of fibroblast growth factor 21 (FGF21)...
...Underwriters are BofA Securities, SVB Leerink, RBC Capital Markets and Oppenheimer. Paul Bonanos, Associate Editor BIO89-100 (TEV-47948) 89bio Inc. Fibroblast growth factor 21 (FGF21) non-alcoholic...
BioCentury | Oct 25, 2019
Tools & Techniques

NASH: how non-invasive biomarkers promise to displace biopsies

...BMS is exploring the marker in Phase IIb trials of NASH compound pegbelfermin, a pegylated FGF-21...
Items per page:
1 - 10 of 61